Sicheniza Ross Friedman Ference Advises Cell Source Ltd. on Reverse Merger
NEW YORK, July 1, 2014 (GLOBE NEWSWIRE) —
New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Cell Source Limited (Israel) in a reverse merger transaction whereby Cell Source Inc., a Nevada based publicly traded company under the symbol “CLCS: OTCQB”, acquired 100% of the capital stock of Cell Source Limited, an Israeli biotechnology company engaged in developing cell therapy treatments.
This past February, Sichenzia Ross represented Cell Source Limited in a private placement transaction consisting of 4.8 million units of securities raising approximately $3.6 million. Each unit consisted of one share of common stock and one common stock purchase warrant.
The Sichenzia Ross Friedman Ference LLP team was led by partner Gregory Sichenzia, David Manno and associate Jay Yamamoto.
Sichenzia Ross Media Contact:
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020
- Coronavirus (Covid 19) Update - March 16, 2020
- Founding Partner Gregory Sichenzia Featured in Law360 Article on Coronavirus-fueled Market Volatility - March 10, 2020